Hypertension, Vol 23, 44-51, Copyright © 1994 by American Heart Association
ND Fisher, D Allan, I Kifor, CL Gaboury, GH Williams, TJ Moore and NK Hollenberg
We compared the renal vascular responses to angiotensin converting enzyme
inhibition and renin inhibition to assess the influence of angiotensin II
(Ang II). We examined the renal and endocrine responses to the renin
inhibitor enalkiren, to captopril, and to placebo in nine healthy and nine
hypertensive men on a 10-mmol sodium diet. Ang II was infused to assess
effects of the agents on renal and adrenal responsiveness to Ang II. Plasma
Ang II concentration was suppressed similarly with enalkiren and
captopril--an identical level of blockade was achieved. Although renal
plasma flow was stable during placebo, a substantial rise was seen with
both enalkiren (+133 +/- 26 mL/min per 1.73 m2) and captopril (+99.4 +/-
22.6). There was remarkable intrasubject concordance between the renal
plasma flow responses to renin inhibition and converting enzyme inhibition
(r = .90, P < .004). The vasodilator response to both agents correlated
inversely with the fall in renal plasma flow induced by Ang II alone (r =
-.66, P < .05). Both agents significantly enhanced the renal vascular
response to Ang II (P = .01), and, furthermore, the renal vasodilator
response to captopril predicted the potentiation of the renal plasma flow
response to Ang II after either agent (enalkiren: r = .91, P < .001;
captopril: r = .56, P < .05). Concordance of the maximal renal plasma
flow response to the two agents appeared in the hypertensive men as well.
Our results indicate that the acute renal response to captopril largely
reflects a reduction in Ang II formation.(ABSTRACT TRUNCATED AT 250 WORDS)
ARTICLES
Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans
Department of Medicine, Harvard Medical School, Boston, Mass.
This article has been cited by other articles:
 |
|
 |
|
  N. D.L. Fisher, A.H. Jan Danser, J. Nussberger, W. P. Dole, and N. K. Hollenberg Renal and Hormonal Responses to Direct Renin Inhibition With Aliskiren in Healthy Humans Circulation, June 24, 2008; 117(25): 3199 - 3205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Segall, A. Covic, and D. J. A. Goldsmith Direct renin inhibitors: the dawn of a new era, or just a variation on a theme? Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2435 - 2439. [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Perlstein, M. Gerhard-Herman, N. K. Hollenberg, G. H. Williams, and A. Thomas Insulin Induces Renal Vasodilation, Increases Plasma Renin Activity, and Sensitizes the Renal Vasculature to Angiotensin Receptor Blockade in Healthy Subjects J. Am. Soc. Nephrol., March 1, 2007; 18(3): 944 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. K Hollenberg Spotlight on Renin: Therapeutic opportunities for renin inhibitors Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2): 107 - 109. [PDF]
|
|
|
|
|
|
N. D.L. Fisher and N. K. Hollenberg Renin Inhibition: What Are the Therapeutic Opportunities? J. Am. Soc. Nephrol., March 1, 2005; 16(3): 592 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Unger and Jun Li The role of the renin-angiotensin-aldosterone system in heart failure Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1_suppl): S7 - S10. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Stanton, C. Jensen, J. Nussberger, and E. O'Brien Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, Aliskiren Hypertension, December 1, 2003; 42(6): 1137 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Stanton Review: Potential of renin inhibition in cardiovascular disease Journal of Renin-Angiotensin-Aldosterone System, March 1, 2003; 4(1): 6 - 10. [Abstract] [PDF]
|
|
|
|
|
|
D. A. Price, N. D.L. Fisher, M. C. Lansang, R. Stevanovic, G. H. Williams, and N. K. Hollenberg Renal Perfusion in Blacks: Alterations Caused by Insuppressibility of Intrarenal Renin With Salt Hypertension, August 1, 2002; 40(2): 186 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Lansang, S. Y. Osei, D. A. Price, N. D. L. Fisher, and N. K. Hollenberg Renal Hemodynamic and Hormonal Responses to the Angiotensin II Antagonist Candesartan Hypertension, November 1, 2000; 36(5): 834 - 838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S Weinberg, A. J Weinberg, and D. H Zappe Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 217 - 233. [PDF]
|
|
|
|
|
|
P. van Paassen, D. de Zeeuw, G. Navis, and P. E. de Jong Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function Nephrol. Dial. Transplant., May 1, 2000; 15(5): 637 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. K. Hollenberg Implications of Species Difference for Clinical Investigation : Studies on the Renin-Angiotensin System Hypertension, January 1, 2000; 35(1): 150 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Gainer, J. D. Morrow, A. Loveland, D. J. King, and N. J. Brown Effect of Bradykinin-Receptor Blockade on the Response to Angiotensin-Converting-Enzyme Inhibitor in Normotensive and Hypertensive Subjects N. Engl. J. Med., October 29, 1998; 339(18): 1285 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. K. Hollenberg, N. D. L. Fisher, and D. A. Price Pathways for Angiotensin II Generation in Intact Human Tissue : Evidence From Comparative Pharmacological Interruption of the Renin System Hypertension, September 1, 1998; 32(3): 387 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Price, J. M. De'Oliveira, N. D. L. Fisher, and N. K. Hollenberg Renal Hemodynamic Response to an Angiotensin II Antagonist, Eprosartan, in Healthy Men Hypertension, August 1, 1997; 30(2): 240 - 246. [Abstract] [Full Text]
|
|
|
|
|
|
N. K. Hollenberg and N. D. L. Fisher Renal Circulation and Blockade of the Renin-Angiotensin System : Is Angiotensin-Converting Enzyme Inhibition the Last Word? Hypertension, October 1, 1995; 26(4): 602 - 609. [Abstract] [Full Text]
|
|
|
|
|
|
N. D. L. Fisher, D. R. Allan, C. L. Gaboury, and N. K. Hollenberg Intrarenal Angiotensin II Formation in Humans : Evidence From Renin Inhibition Hypertension, May 1, 1995; 25(5): 935 - 939. [Abstract] [Full Text]
|
|
|
|
|
|
P. N. Hopkins, S. C. Hunt, X. Jeunemaitre, B. Smith, D. Solorio, N. D.L. Fisher, N. K. Hollenberg, and G. H. Williams Angiotensinogen Genotype Affects Renal and Adrenal Responses to Angiotensin II in Essential Hypertension Circulation, April 23, 2002; 105(16): 1921 - 1927. [Abstract] [Full Text] [PDF]
|
|